Table 1.
Selected sociodemographic and breast cancer clinicopathologic characteristics among incident breast cancer cases diagnosed in New Jersey, 2008–2013, N = 32,770.
| Characteristics | n | (%) | |
|---|---|---|---|
| Sociodemographic characteristics | |||
| Age at diagnosis (years) | |||
| 20–39 | 1,773 | (5.4) | |
| 40–49 | 6,344 | (19.3) | |
| 50–64 | 12,179 | (37.1) | |
| ≥65 | 12,474 | (38.0) | |
| Race/ethnicity | |||
| White, non-Hispanic | 23,930 | (73.0) | |
| Black, non-Hispanic | 3,829 | (11.7) | |
| Asian/Pacific Islander, non-Hispanic | 1,826 | (5.6) | |
| Hispanic (any race) | 2,831 | (8.6) | |
| Other/unknown | 354 | (1.1) | |
| Breast cancer clinicopathologic characteristics | |||
| Primary site of breast cancer | |||
| Nipple (areolar) | 152 | (0.5) | |
| Central (sub-areolar) | 1,509 | (4.6) | |
| Upper inner quadrant | 3,513 | (10.7) | |
| Lower inner quadrant | 1,767 | (5.4) | |
| Upper outer quadrant | 10,760 | (32.8) | |
| Lower outer quadrant | 2,286 | (7.0) | |
| Axillary tail | 158 | (0.5) | |
| Overlapping lesion | 6,532 | (19.9) | |
| Breast, NOS | 6,093 | (18.6) | |
| Cancer sequence number | |||
| One primary cancer diagnosed | 29,373 | (89.6) | |
| First of two or more primaries diagnosed | 3,397 | (10.3) | |
| Histology | |||
| Adenocarcinoma | 613 | (1.9) | |
| Ductal carcinoma | 23,948 | (73.1) | |
| Lobular carcinoma | 3,074 | (9.4) | |
| Ductal and lobular carcinoma | 1,942 | (5.9) | |
| Mixeda | 1,086 | (3.3) | |
| Other/unknownb | 2,107 | (6.4) | |
| Tumor stagec | |||
| Localized | 20,117 | (61.4) | |
| Regional | 9,810 | (29.9) | |
| Distant | 2,039 | (6.2) | |
| Unknown | 804 | (2.5) | |
| Tumor grade | |||
| Well differentiated | 4,883 | (14.9) | |
| Moderately differentiated | 13,364 | (40.7) | |
| Poorly differentiated | 11,140 | (34.0) | |
| Missing/unknown | 3,383 | (10.3) | |
| ER status (SSF 1) | |||
| Positive | 25,750 | (78.6) | |
| Negative | 5,656 | (17.3) | |
| Borderline | 27 | (0.1) | |
| Other/unknown | 1,337 | (4.1) | |
| PR status (SSF 2) | |||
| Positive | 22,518 | (68.7) | |
| Negative | 8,768 | (26.8) | |
| Borderline | 102 | (0.3) | |
| Other/unknown | 1,382 | (4.2) | |
| HER2 IHC lab value (SSF 8) | |||
| 0 | 4,318 | (13.1) | |
| 1+ | 5,750 | (17.5) | |
| 2+ | 2,760 | (8.4) | |
| 3 | 2,019 | (6.2) | |
| Unknown | 17,923 | (54.4) | |
| HER2 IHC interpretation (SSF 9) | |||
| Positive | 2,484 | (7.7) | |
| Negative | 11,875 | (36.5) | |
| Borderline | 2,414 | (7.4) | |
| Other/unknown | 15,997 | (48.4) | |
| HER2 FISH lab value (SSF 10) | |||
| 1.00–9.79 | 11,889 | (36.3) | |
| 9.80–9.87 | 127 | (0.4) | |
| Other/unknown | 20,754 | (63.3) | |
| HER2 FISH interpretation (SSF 11) | |||
| Positive | 2,185 | (6.7) | |
| Negative | 12,153 | (37.3) | |
| Borderline | 410 | (1.3) | |
| Other/unknown | 18,022 | (54.7) | |
| HER2 CISH lab value (SSF 12) | |||
| 1.00–9.79 | 32 | (0.1) | |
| 9.80–9.87 | 15 | (0.1) | |
| Other/unknown | 32,723 | (99.8) | |
| HER2 CISH interpretation (SSF 13) | |||
| Positive | 30 | (0.1) | |
| Negative | 164 | (0.5) | |
| Borderline | 10 | (0.1) | |
| Other/unknown | 32,566 | (99.4) | |
| HER2 result of other or unknown test (SSF 14) | |||
| Positive | 768 | (2.4) | |
| Negative | 5,351 | (16.5) | |
| Borderline | 166 | (0.5) | |
| Other/unknown | 26,485 | (80.6) | |
| HER2 summary result (SSF 15) | |||
| Positive | 4,373 | (13.5) | |
| Negative | 24,268 | (74.0) | |
| Borderline | 630 | (1.9) | |
| Other/unknown | 3,499 | (10.0) | |
| Breast cancer subtype (SSF 16) | |||
| Luminal A (ER+ and/or PR+/HER2-) | 20,775 | (63.3) | |
| Luminal B (ER+ and/or PR+/HER+) | 2,938 | (8.9) | |
| Non-luminal HER2-expressing (ER-/PR-/HER2+) | 1,396 | (4.2) | |
| Triple-negative (ER-/PR-/HER2-) | 3,346 | (10.2) | |
| Unknown | 4,315 | (13.1) | |
| Vital statusd | |||
| Dead | 5,734 | (17.5) | |
| Alive | 27,036 | (82.5) | |
NOTE: Percentages may not sum to 100 due to rounding. P values were generated using chi-square test. Abbreviations: CS SSF, Collaborative Stage Site-Specific Factor; ER, estrogen receptor; CISH, chromogenic in situ hybridization; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor 2; IHC, immunohistochemistry; NOS, not otherwise specified; PR, progesterone receptor
Mixed histology includes breast cancers classified as: duct and cribriform carcinoma, duct and mucinous carcinoma, duct and tubular carcinoma, or duct and colloid carcinoma.
Other & unknown histology includes breast cancers classified as: neoplasm, tumor cells, carcinoma NOS, pleomorphic carcinoma, spindle cell carcinoma NOS, pseudosarcomatous carcinoma, small cell carcinoma NOS, papillary carcinoma, squamous cell carcinoma NOS, squamous cell carcinoma keratinizing NOS, basaloid carcinoma, adenocarcinoma, adenocarcinoma NOS, scirrhous adenocarcinoma, adenoid cystic carcinoma, cribriform carcinoma NOS, tubular adenocarcinoma, solid carcinoma NOS, neuroendocrine carcinoma, adenocarcinoma with mixed subtypes, papillary adenocarcinoma NOS, clear cell adenocarcinoma NOS, glycogen-rich carcinoma, mixed cell adenocarcinoma, apocrine adenocarcinoma, papillary serous cystadenocarcinoma, mucinous cystadenocarcinoma NOS, mucin producing adenocarcinoma, signet ring cell carcinoma, comedenocarcinoma NOS, secretory carcinoma of breast, intraductal papillary adenocarcinoma with invasion, intracystic carcinoma NOS, medullary carcinoma NOS, atypical medullary carcinoma, infiltrating ductular carcinoma, Infiltrating lobular mixed with other types of carcinoma, inflammatory carcinoma, Paget’s disease (mammary), Paget’s disease with intraductal carcinoma of breast, adenosquamous carcinoma, adenocarcinoma with spindle cell metaplasia, adenocarcinoma with neuroendocrine differentiation, metaplastic carcinoma NOS, sarcoma NOS, giant cell sarcoma, epithelioid sarcoma, malignant fibrous histiocytoma, liposarcoma NOS, myxoid liposarcoma, leiomyomatosis NOS, spindle cell rhabdomyosarcoma, stromal sarcoma NOS, carcinosarcoma NOS, malignant myoepithelioma, phyllodes tumor, hemangiosarcoma, or osteosarcoma NOS.
SEER summary stage.
Vital status as of December 31, 2014.